Loading
A phase 3 trial testing PM8002 in triple-negative breast cancer, active and no longer recruiting.
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC is a phase 3 interventional study registered as NCT06419621, led by Biotheus, and active but no longer recruiting on the registry. Official title: A Multicenter, Randomised, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC). Planned enrolment is 392 participants (estimated). The study started in 2024-06-11 and primary completion is expected in 2027-07. No results have been posted on ClinicalTrials.gov.
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC).